A Randomized, Multicenter, Double blind, Single doses Study Comparing the Pharmacodynamic, Pharmacokinetic and Safety of Biosimilar EPTACOG Alfa with Novoseven, in Patient with Hemophilia A or B with Inhibitors

Trial Profile

A Randomized, Multicenter, Double blind, Single doses Study Comparing the Pharmacodynamic, Pharmacokinetic and Safety of Biosimilar EPTACOG Alfa with Novoseven, in Patient with Hemophilia A or B with Inhibitors

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors AryoGen Pharmed
  • Most Recent Events

    • 21 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top